Giulia Benedetti

Giulia Benedetti

Auto-generated profile, based on publicly available information

Giulia Benedetti

Cardiology Department, Guy's and St Thomas’ NHS Foundation Trust

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in JACC
Verified
Journal Article
Open access
TTThomas A Treibel
Thomas A Treibel
RKRebecca Kozor
Rebecca Kozor
RSRebecca Schofield
Rebecca Schofield
GBGiulia Benedetti
Giulia Benedetti
MFMarianna Fontana
Marianna Fontana
JMJames C. Moon
James C. Moon
Left ventricular (LV) hypertrophy, a key process in human cardiac disease, results from cellular (hypertrophy) and extracellular matrix expansion (interstitial fibrosis). This study sought to investigate whether human myocardial interstitial fibrosis in aortic stenosis (AS) is plastic and can regress. Patients with symptomatic, severe AS (n = 181; aortic valve area index 0.4 ± 0.1 cm2/m2) were assessed pre-aortic valve replacement (AVR) by echocardiography (AS severity, diastology), cardiovascular magnetic resonance (CMR) (for volumes, function, and focal or diffuse fibrosis), biomarkers (N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T), and the 6-min walk test. CMR was used to measure the extracellular volume fraction (ECV), thereby deriving matrix volume (LV mass × ECV) and cell volume (LV mass × [1 - ECV]). Biopsy excluded occult bystander disease. Assessment was repeated at 1 year post-AVR. At 1 year post-AVR in 116 pacemaker-free survivors (age 70 ± 10 years; 54% male), mean valve gradient had improved (48 ± 16 mm Hg to 12 ± 6 mm Hg; p < 0.001), and indexed LV mass had regressed by 19% (88 ± 26 g/m2 to 71 ± 19 g/m2; p < 0.001). Focal fibrosis by CMR late gadolinium enhancement did not change, but ECV increased (28.2 ± 2.9% to 29.9 ± 4.0%; p < 0.001): this was the result of a 16% reduction in matrix volume (25 ± 9 ml/m2 to 21 ± 7 ml/m2; p < 0.001) but a proportionally greater 22% reduction in cell volume (64 ± 18 ml/m2 to 50 ± 13 ml/m2; p < 0.001). These changes were accompanied by improvement in diastolic function, N-terminal pro-B-type natriuretic peptide, 6-min walk test results, and New York Heart Association functional class. Post-AVR, focal fibrosis does not resolve, but diffuse fibrosis and myocardial cellular hypertrophy regress. Regression is accompanied by structural and functional improvements suggesting that human diffuse fibrosis is plastic, measurable by CMR and a potential therapeutic target. (Regression of Myocardial Fibrosis After Aortic Valve Replacement; NCT02174471).

1 May 2019 in Heart Rhythm
Verified
Journal Article
Closed access
Giovanni PerettoGiovanni Peretto
Giovanni Peretto
SSSimone Sala
Simone Sala
SRStefania Rizzo
Stefania Rizzo
GLGiacomo De Luca
Giacomo De Luca
Corrado CampochiaroCorrado Campochiaro
Corrado Campochiaro
PBPaolo Della Bella
Paolo Della Bella

1 January 2016 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
GCGabriella Captur
Gabriella Captur
PGPeter Gatehouse
Peter Gatehouse
KKKathryn E. Keenan
Kathryn E. Keenan
FHFriso G. Heslinga
Friso G. Heslinga
RBRuediger Bruehl
Ruediger Bruehl
JMJames C. Moon
James C. Moon
T1 mapping and extracellular volume (ECV) have the potential to guide patient care and serve as surrogate end-points in clinical trials, but measurements differ between cardiovascular magnetic resonance (CMR) scanners and pulse sequences. To help deliver T1 mapping to global clinical care, we developed a phantom-based quality assurance (QA) system for verification of measurement stability over time at individual sites, with further aims of generalization of results across sites, vendor systems, software versions and imaging sequences. We thus created T1MES: The T1 Mapping and ECV Standardization Program. A design collaboration consisting of a specialist MRI small-medium enterprise, clinicians, physicists and national metrology institutes was formed. A phantom was designed covering clinically relevant ranges of T1 and T2 in blood and myocardium, pre and post-contrast, for 1.5 T and 3 T. Reproducible mass manufacture was established. The device received regulatory clearance by the Food and Drug Administration (FDA) and Conformité Européene (CE) marking. The T1MES phantom is an agarose gel-based phantom using nickel chloride as the paramagnetic relaxation modifier. It was reproducibly specified and mass-produced with a rigorously repeatable process. Each phantom contains nine differently-doped agarose gel tubes embedded in a gel/beads matrix. Phantoms were free of air bubbles and susceptibility artifacts at both field strengths and T1 maps were free from off-resonance artifacts. The incorporation of high-density polyethylene beads in the main gel fill was effective at flattening the B 1 field. T1 and T2 values measured in T1MES showed coefficients of variation of 1 % or less between repeat scans indicating good short-term reproducibility. Temperature dependency experiments confirmed that over the range 15–30 °C the short-T1 tubes were more stable with temperature than the long-T1 tubes. A batch of 69 phantoms was mass-produced with random sampling of ten of these showing coefficients of variations for T1 of 0.64 ± 0.45 % and 0.49 ± 0.34 % at 1.5 T and 3 T respectively. The T1MES program has developed a T1 mapping phantom to CE/FDA manufacturing standards. An initial 69 phantoms with a multi-vendor user manual are now being scanned fortnightly in centers worldwide. Future results will explore T1 mapping sequences, platform performance, stability and the potential for standardization.

29 November 2019 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
APAnna Palmisano
Anna Palmisano
DVDavide Vignale
Davide Vignale
GBGiulia Benedetti
Giulia Benedetti
AMAlessandro Del Maschio
Alessandro Del Maschio
FCFrancesco De Cobelli
Francesco De Cobelli
AEAntonio Esposito
Antonio Esposito

1 May 2020 in Radiology
Verified
Journal Article
Closed access
APAnna Palmisano
Anna Palmisano
GBGiulia Benedetti
Giulia Benedetti
RFRiccardo Faletti
Riccardo Faletti
PRPaola M.V. Rancoita
Paola M.V. Rancoita
MGMarco Gatti
Marco Gatti
AEAntonio Esposito
Antonio Esposito
Early myocardial T1 shortening can be used to quantify myocardial hyperemia in participants with acute myocarditis. Background Hyperemia is a key component of acute myocarditis (AM). Early gadolinium uptake because of myocardial hyperemia may be quantified by using T1 mapping. Purpose To evaluate the value of ea...

1 June 2017 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
ADAlessandro Durante
Alessandro Durante
ALAlessandra Laricchia
Alessandra Laricchia
GBGiulia Benedetti
Giulia Benedetti
AEAntonio Esposito
Antonio Esposito
AMAlberto Margonato
Alberto Margonato
PCPaolo G. Camici
Paolo G. Camici
Background—: The incidence of angiographic no reflow (NR) and microvascular obstruction (MVO) at cardiac magnetic resonance is significantly different. The aim of this study was to investigate the occurrence of NR and MVO in a cohort of consecutive patients with ST-segment–elevation myocardial infarction treated with primary percutaneous coronary interventions. Methods and Results—: In this prospective study, 88 consecutive ST-segment–elevation myocardial infarction patients were enrolled within 12 hours from symptoms onset. All patients underwent cardiac magnetic resonance between 2 and 5 days after primary percutaneous coronary interventions. NR was defined as thrombolysis in myocardial infarction flow grade ≤2 and as myocardial blush grade <2. Presence of early or late MVO was assessed 4 and 10 to 15 minutes after gadolinium injection. Thirty-one patients (36%) had evidence of NR, whereas 58 (67%) had MVO. One NR patient did not have MVO. In contrast, NR was present in 30 of 58 MVO patients. MVO patients had higher troponin T peak ( P <0.0001), larger late gadolinium enhancement area ( P <0.0001), and lower left ventricular ejection fraction ( P <0.001) because of an increased end-systolic volume ( P =0.015). In contrast, patients with NR had higher troponin T peak ( P =0.006) but similar late gadolinium enhancement area ( P =0.24) compared with those without NR. Major cardiovascular adverse events–free survival was worse in patients with MVO ( P =0.014), although it was similar in patients with and without NR ( P =0.33). The independent predictors of major cardiovascular adverse events were MVO (hazard ratio, 3.418; P =0.046) and ischemic time (hazard ratio, 1.016; P <0.001). MVO was a strong predictor of target lesion revascularization occurrence ( P =0.017 for log-rank test). Conclusions—: Compared with coronary angiography performed soon after recanalization of the culprit artery, cardiac magnetic resonance performed during index hospitalization provides better prognostic stratification of ST-segment–elevation myocardial infarction patients treated with primary percutaneous coronary interventions. Another novel finding of our study is a significantly increased rate of clinically driven target lesion revascularization in the index event culprit vessel in patients with MVO.